Un trasplante que utiliza las propias células madre del paciente (trasplante autólogo de células madre) o la terapia de células CAR T son opciones de tratamiento para pacientes con ciertos tipos de linfoma.
A menudo se utiliza un trasplante de células madre para tratar a pacientes con mieloma múltiple. La terapia de mantenimiento después del trasplante puede prolongar la remisión y prolongar la vida del paciente.
Download Speaker Slides Major Treatment Decisions for Patients with Acute Myeloid Leukemia or AML Monday, October 17, 2022 Presenter: Fred Applebaum, MD, Executive Vice President and Deputy Director of the
Download Speaker Slides Transplantation for Myelodysplastic Syndromes: Who, When, and How? Wednesday, October 27, 2021 Presenter: Dr. Nandita Khera, MD, MPH, Associate Professor of Medicine, Mayo Clinc Presentation is 29
Download Speaker Slides Acute Myeloid Leukemia: Increasing Complexity and Increasing Treatment Opportunities Thursday, October 14, 2021 Presenter: Dr. Mark R. Litzow, MD, Professor of Medicine, Mayo Clinic Presentation is 42
Download Speaker Slides Treatment Options for Patients with Sickle Cell Disease Wednesday, August 11, 2021 Presenters: Alison Towerman MSN, RN, CPNP and Hemalatha Rangarajan MD Presentation is 47 minutes long
Download Speaker Slides Transplant Outcomes in Older Adults with MDS and AML Monday, April 19, 2021 Presenter: Gabrielle Meyers MD, Associate Professor, Center for Hematologic Malignancies, Oregon Health & Science
Download Speaker Slides Multiple Myeloma: Stem Cell Transplant and Beyond Wednesday, April 21, 2021 Presenter: Frits van Rhee MD, PhD, Professor of Medicine and Clinical Director of the UAMS Myeloma
Presented by Matthew Matasar MD, Assistant Member of Lymphoma and Adult BMT Services, and Medical Director of the Lymphoma Survivorship Clinic at Memorial Sloan Kettering Cancer Center Run time: 56
Presented by Dr. Patrick Stiff, Cardinal Bernardin Cancer Center, Loyola University Medical Center Run Time: 60 minute presentation, 30 minutes Q&A Made possible, in part, by support from Miltenyi Biotec
